NCT05561712 is a clinical trial of Laboratory method validation in NAD, sponsored by Société des Produits Nestlé (SPN).

Who is sponsoring NCT05561712?

NCT05561712 is sponsored by Société des Produits Nestlé (SPN).

What drugs are being tested in NCT05561712?

Interventions in NCT05561712: Laboratory method validation.

Is NCT05561712 still recruiting?

NCT05561712 is currently completed. Last updated 30 September 2022.

Last reviewed 2022-09-30 · How we verify

NCT05561712

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Method Optimization for the Quantification of the NAD

Completed Last updated 30 September 2022

What this trial tests

trial testing Laboratory method validation in NAD in 10 participants. Completed in 15 March 2022.

Timeline

25 February 2022

Primary endpoint
15 March 2022

15 March 2022

Quick facts

Lead sponsor	Société des Produits Nestlé (SPN)
Status	Completed
Study type	OBSERVATIONAL
Enrollment	10
Start date	25 February 2022
Primary completion	15 March 2022
Estimated completion	15 March 2022
Sites	1 location across Switzerland

Drugs / interventions tested

Laboratory method validation

Conditions studied

NAD — all drugs for NAD →

Sponsor

Société des Produits Nestlé (SPN) — full company profile →

Who can join

Adults 18 to 55, any sex, with NAD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Method optimization for the quantification of the NAD metabolome in human whole blood, and evaluation of baseline inter and intra-subject variability.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for NAD

Currently open trials in the same condition.

NCT07203131 — Evaluation of the Impact of an Alteration of NAD+ Metabolism on the Renal Prognosis of Patients Admitted to Intensive Ca · NA · recruiting
NCT06005350 — Nicotinamide Riboside Impact on Extracellular Nicotinamide Adenine Dinucleotide (NAD+) · NA · active not recruiting

Other Société des Produits Nestlé (SPN) trials

Trials by the same sponsor.

NCT07312201 — Oral Nutritional Supplementation in Children With Growth Concerns · NA · not yet recruiting
NCT07378111 — Vegetarian Tube Feed Study · NA · not yet recruiting
NCT07439718 — The Effects of an Oral Nutritional Intervention on the Small Intestine Microbiome · NA · recruiting
NCT07341464 — Acceptability and Tolerance Study of Bolus Tube Feed With Food Blends · NA · recruiting
NCT07127198 — Tolerance and Appetite Reduction of a Nutritional Solution With Intragastric Gelation Properties · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05561712 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Société des Produits Nestlé (SPN)
Last refreshed: 30 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05561712.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing